Top

Drugs & Aging

Published in:

01-05-2007 | Leading Article

Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis

Progress to Date

Authors: Dr Jean-Yves Reginster, Olivier Malaise, Audrey Neuprez, Victor-Emmanuel Jouret, Pierre Close

Published in: Drugs & Aging | Issue 5/2007

Abstract

Bisphosphonates are the most widely prescribed drugs in osteoporosis today. They have unequivocally shown their ability to reduce fracture rate at the spine (alendronic acid, risedronic acid, ibandronic acid) and at the hip (alendronic acid and risedronic acid). However, their dosage and administration procedures and the adverse reactions induced by their oral intake are responsible for low adherence. Therefore, intermittent regimens have been developed. Weekly alendronic acid and risedronic acid provide similar benefits, in terms of bone mineral density (BMD) and changes in biochemical markers, as those seen with their daily formulations. Ibandronic acid has been shown to reduce vertebral fractures when given intermittently. Ibandronic acid given orally monthly and intravenously every 2 or 3 months provides increases in BMD similar to the daily formulation. Yearly intravenous infusions of zoledronic acid are currently being evaluated for their ability to reduce fractures. If the efficacy and safety of bisphosphonates given at administration intervals longer than weekly are confirmed, this might significantly improve patient adherence and long-term outcomes of bisphosphonate treatment in postmenopausal osteoporosis.

Boonen S, Body JJ, Boutsen Y, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteopros Int 2005; 16: 239–54CrossRef

Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006; 38: S2–6PubMedCrossRef

de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016–21PubMedCrossRef

Reginster JY, Rabenda V. Adherence to anti-osteoporotic treatment: does it really matter? Future Rheumatol 2006; 1: 37–40CrossRef

Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006; 38: S18–21PubMedCrossRef

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296–310PubMedCrossRef

Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28: 236–42PubMedCrossRef

Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; 2: 1469–71PubMedCrossRef

Reginster JY, Christiansen C, Roux C, et al. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int 2001; 12: 169–77PubMedCrossRef

10.

Hodsman AB. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. Bone Miner 1989; 5: 201–12PubMedCrossRef

11.

Watts BN, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73–9PubMedCrossRef

12.

Storm T, Thamsborg G, Steiniche T, et al. Effect on intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265–71PubMedCrossRef

13.

Thomas T, Lafage MH, Alexandre C. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. J Rheumatol 1995; 22: 2183–5PubMed

14.

MacGowan JR, Pringle J, Morris VH, et al. Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget’s disease. Skeletal Radiol 2000; 29: 279–82PubMedCrossRef

15.

Eyres KS, Marshall P, McCloskey E, et al. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf 1992; 7: 162–5PubMedCrossRef

16.

Thiebaud D, Burckhardt P, Melchior J, et al. Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994; 4: 76–83PubMedCrossRef

17.

Peretz A, Body JJ, Dumon JC, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996; 25: 69–75PubMedCrossRef

18.

Ryan PJ, Blake GM, Davie M, et al. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety. Osteo-poros Int 2000; 11: 171–6CrossRef

19.

Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17: 1659–65PubMedCrossRef

20.

Black DM, Cummings SR, Karpf DB, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alen-dronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41PubMedCrossRef

21.

Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of vertebral fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–82PubMedCrossRef

22.

Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endoc Rev 2002; 23: 508–16CrossRef

23.

Schnitzer T, Bone HG, Crepaldi G, et al. Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1–12

24.

Rizzoli R, Greenspan SL, Bone III G, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988–96PubMedCrossRef

25.

Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003; 101: 711–21PubMedCrossRef

26.

Uchida S, Taniguchi T, Shimizu T, et al. Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 2005; 23: 382–8PubMedCrossRef

27.

Rossini M, Gatti D, Girardello S, et al. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000; 27: 119–22PubMedCrossRef

28.

Chailurkit LO, Aunphongpuwanart S, Ongphiphadhanakul B, et al. Efficacy of intermittent low dose alendronate in Thai postmenopausal osteoporosis. Endocr Res 2004; 30: 29–36PubMedCrossRef

29.

Close P, Neuprez A, Reginster JY. Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 2006; 7: 1603–15PubMedCrossRef

30.

Harris ST, Watts NB, Genant HK, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344–52PubMedCrossRef

31.

Reginster JY, Minne HW, Sorensen OH, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83–91PubMedCrossRef

32.

McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333–40PubMedCrossRef

33.

Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis: III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517–23PubMedCrossRef

34.

Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 101–11

35.

Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004; 20: 757–64PubMedCrossRef

36.

Sebba AI, Bonnick SL, Kagan R, et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2004; 20: 2031–41PubMedCrossRef

37.

Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006; 91: 2631–7PubMedCrossRef

38.

Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20: 141–51PubMedCrossRef

39.

Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241–9CrossRef

40.

Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005; 90: 5018–24PubMedCrossRef

41.

Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–22PubMedCrossRef

42.

Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654–61PubMedCrossRef

43.

Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895–903PubMedCrossRef

44.

Cooper A, Drake J, Brankin E, et al. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896–905PubMedCrossRef

45.

Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838–46PubMedCrossRef

46.

Reid DM. Once-monthly dosing: an effective step forward. Bone 2006; 38 Suppl.: S18–22PubMedCrossRef

47.

Reginster JY. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des 2005; 11: 3711–28PubMedCrossRef

48.

Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for PagetZ’s disease. N Engl J Med 2005; 353: 898–908PubMedCrossRef

49.

Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653–61PubMedCrossRef

50.

Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054–9PubMedCrossRef

51.

Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 2006; 17: 1197–204PubMedCrossRef

52.

Kuehn BM. Reports of adverse events from bone drugs prompt caution. JAMA 2006; 295: 2833–6PubMedCrossRef

Title: Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis
Progress to Date
Authors: Dr Jean-Yves Reginster
Olivier Malaise
Audrey Neuprez
Victor-Emmanuel Jouret
Pierre Close
Publication date: 01-05-2007
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 5/2007
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200724050-00001

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis

Progress to Date

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2007

Oral Anticancer Drugs in the Elderly

Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with Statins

Docetaxel in Non-Small Cell Lung Cancer

Optimal Management of Asthma in Elderly Patients

Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page